When it is combined with CUM, the combination shows a synergistic action in inhibiting the growth of head and neck cancer and other tumour cell lines causing a good clinical response and a significant reduction in the biomarkers p53, cyclin D1 and Ki67 after three months of treatment. The gene discussed is CCND1; the disease is neoplasm.